Articles Tagged: Clinical Trial
April 15, 2014 | Category: News
“Chondroitinase improves the outcome after spinal cord injuries in lab animals; therefore it could also benefit dogs and people suffering from the same conditions.”
The purpose of our clinical trial is to help these severely affected dogs by testing if a new treatment, called chondroitinase, may improve the outcome after spinal cord injury in dogs.
“Spinal cord injuries can lead to serious consequences including the impairment of movement, sensation and urination; this is because spinal cord tissue does not regenerate effectively” Continue Reading »
Rutgers’ Wise Young and Army Capt. Boyd Melson fight to bring clinical trials to the United States
What would one of the world’s leading researchers in spinal cord injury and a professional boxer have in common? Under normal circumstances not much.
But Wise Young, a Rutgers neuroscience professor who is searching for a cure for spinal cord injury, and Boyd Melson, a West Point graduate and Army captain who is dedicating his life and boxing prize money to help make this dream happen, are two men on the same mission. Continue Reading »
October 2, 2013 | Category: News
NEWARK, Calif., Oct. 2, 2013 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company’s Investigational New Drug (IND) application for clinical testing of the Company’s proprietary HuCNS-SC® human neural stem cells as a treatment for spinal cord injury. As a first action under this IND, the Company is working to open U.S. sites for its Phase I/II clinical trial for chronic spinal cord injury, which is currently underway in Switzerland and Canada. Continue Reading »
September 25, 2013 | Category: News
AC105 improved motor function after spinal cord injury in preclinical studies
ARDSLEY, N.Y.–(BUSINESS WIRE)–Sep. 25, 2013– Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the first patient has been enrolled in a trial of AC105, its proprietary magnesium formulation for the treatment of spinal cord injury (SCI). This Phase 2 trial will evaluate the safety and tolerability of the drug in people with traumatic SCI, and also incorporates several exploratory efficacy measures. Continue Reading »
February 12, 2013 | Category: News
StemCells, Inc. Announces First Patient Cohort Completes Spinal Cord Injury Trial – Gains in Sensory Function Persist 12 Months After Stem Cell Transplant
NEWARK, Calif., Feb. 12, 2013 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) today announced that the twelve-month data from the first patient cohort in the Company’s Phase I/II clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) for chronic spinal cord injury continued to demonstrate a favorable safety profile, and showed that the considerable gains in sensory function observed in two of the three patients at the six-month assessment have persisted. Continue Reading »
December 18, 2012 | Category: News
Systemic hypothermia remains a promising neuroprotective strategy. There has been recent interest in its use in patients with spinal cord injury (SCI). In this article, we describe our extended single center experience using intravascular hypothermia for the treatment of cervical SCI. Continue Reading »
September 7, 2012 | Category: News
(CNN) — As the sun rose over France on August 13, 2011, Knut Olstad was looking forward to continuing his bicycle journey along the Tour de France route. But by the end of the day, the vacation had taken a terrible turn that would change his life.
The 46-year-old financial consultant from Norway doesn’t remember much about the accident that left him paralyzed from the chest down. He was shown pictures of himself lying on the ground with a broken back after being catapulted from his bike while trying to avoid a collision with a car. Continue Reading »
June 7, 2011 | Category: News
| Spinal Cord Injury: T-11
MENLO PARK, Calif.- Geron Corporation (Nasdaq: GERN) today announced two presentations on the company’s ongoing Phase 1 clinical trial of the human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury. Data on the first two patients were presented at the 2011 International Conference on Spinal Cord Medicine and Rehabilitation in Washington, D.C. A second presentation was given at the 2011 Spine Symposium, which was held as part of The American Spinal Injury Association (ASIA) Annual Scientific Meeting. The presentations were given by Edward Wirth, III, M.D., Ph.D., Geron’s Medical Director for Cell Therapies and Linda Jones, P.T., M.S., Geron’s Senior Clinical Trials Manager for GRNOPC1. Continue Reading »
May 17, 2011 | Category: News
The California Institute for Regenerative Medicine (CIRM) has recently awarded $25 million dollars to “the first clinical trial based on cells derived from human embryonic stem cells that has been approved by the Federal Drug Administration (FDA).” This clinical trial has been specifically designed to benefit spinal cord injury (SCI) patients. Every year, 12,000 Americans suffer SCIs that permanently alter the quality of their lives. Continue Reading »
There is fresh hope for thousands of paraplegics in New Zealand yearning that someday someone will give them a chance to walk again.
Now, thanks to a 71-year-old Waikato housewife, recruiting for New Zealand’s first clinical trial to treat people with spinal injuries is about to begin. Continue Reading »